Press release
Geron Announces Imetelstat Presentations at Upcoming American Society of Hematology Annual Meeting
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and
About this update from Geron Corporation
[{"type":"text","content":" FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGeron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that three abstracts related to imetelstat, the Company’s first-in-class telomerase inhibitor, have been accepted as poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting to be held from December 11-14, 2021. The abstracts are available on the ASH website at www.hematology.org.\n\n“The abstracts for this year’s ASH Meeting reflect the breadth of ongoing activity with imetelstat from pre-clinical studies in a new indication, as well as use of imetelstat as a single agent and in combination with other therapies, to analyses of clinical data supporting our Phase 3 development,” said Aleksandra Rizo, M.D., Ph.D., Geron’s Chief Medical Officer. “We look forward to continued work in these areas as we expand the potential applications for imetelstat in hematologic malignancies.”\n\nClinical Data – Lower Risk Myelodysplastic Syndromes (MDS)\n\nAbstract Title: On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)\n\nThe abstract describes new analyses of data from the IMerge Phase 2 clinical trial. In the analyses, a significant correlation was observed between achieving an optimal pharmacodynamic (PD) effect in imetelstat-treated patients with durable red blood cell transfusion independence (RBC-TI). In addition, a trend of improved overall survival rate was seen in patients who achieved optimal PD effect. The authors believe these results demonstrate a potential link between imetelstat activity and clinical efficacy. Additionally, patients in IMerge Phase 2 who achieved an optimal PD effect with imetelstat treatment did not have higher rates of cytopenias or liver enzyme elevations compared to patients without an optimal PD effect.\n\nPoster Presentation Details\nAbstract: #2598\nDate: Sunday, December 12, 2021\nTime: 6:00 p.m. – 8:00 p.m. ET\n\nPre-Clinical Data – Pediatric Acute Myeloid Leukemia\n\nAbstract Title: Imetelstat Significantly Reduces Leukemia Stem Cells in Patient-Derived Xenograft Models of Pediatri...